The UI story will be distributed through numerous platforms and audiences by Blue Digital. The expected outcome is increased knowledge of UI's plans to conduct research into the use of ibogaine as part of a continuum of care for opioid addiction and other addictions.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.